AZN

AstraZeneca PLC Healthcare - Pharmaceuticals Investor Relations →

NO
23.2% ABOVE
↓ Approaching Was 24.8% last week
-15% -10% -5% 0% 5% 10% 15%+
Signal Threshold $149.70
14-Week RSI 67
Rel. Volume (14w) This week's trading vs. the 14-week average 0.7x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.05

AstraZeneca PLC (AZN) closed at $184.45 as of 2026-11-13, trading 23.2% above its 200-week moving average of $149.70. The stock is currently moving closer to the line, down from 24.8% last week. The 14-week RSI sits at 67, indicating neutral momentum.

Trading volume is running at 0.7x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.05 ratio) is neutral — neither side is clearly dominating.

Over the past 1700 weeks of data, AZN has crossed below its 200-week moving average 20 times. On average, these episodes lasted 10 weeks. Historically, investors who bought AZN at the start of these episodes saw an average one-year return of +21.3%.

With a market cap of $286.1 billion, AZN is a large-cap stock. The company generates a free cash flow yield of 2.0%. Return on equity stands at 22.6%, indicating strong profitability. The stock trades at 5.5x book value.

Over the past 32.7 years, a hypothetical investment of $100 in AZN would have grown to $5109, compared to $2964 for the S&P 500. That represents an annualized return of 12.8% vs 10.9% for the index — confirming AZN as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been growing at a 6.2% compound annual rate, with 4 consecutive years of positive cash generation.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: AZN vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After AZN Crosses Below the Line?

Across 20 historical episodes, buying AZN when it crossed below its 200-week moving average produced an average return of +21.0% after 12 months (median +20.0%), compared to +6.3% for the S&P 500 over the same periods. 95% of those episodes were profitable after one year. After 24 months, the average return was +42.5% vs +20.7% for the index.

Each line shows $100 invested at the moment AZN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices AZN would reach each dislocation threshold.

Current Bean Score -1.77σ
Current FCF Yield 2.13%
Baseline Yield 2.51%
Historical σ 0.31pp

Dislocation Price Levels

Prices where AZN's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-09-30).

LevelσPriceSignal
Deep Value+2σ$119.13Unusually cheap — analysis point
Value+1σ$131.47Cheap vs. own history
Fair Value+0σ$146.66Historical mean behavior
Expensive-1σ$165.82Expensive vs. own history
Deep Expensive-2σ$190.73Unusually expensive — analysis point

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Recent Earnings

DateEPS Est.EPS ActualSurprise
2026-10-30$1.15$1.00-12.7%
2026-07-27$1.25$1.32+4.8%
2026-04-29$1.27$1.29+1.4%
2025-11-06$1.13$1.19+4.9%
Data depth: 2 quarterly baselines, 19 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

21 / 13 weeks minimum

the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from AZN's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

⚠ Earnings quality deteriorating — net income is outrunning free cash flow vs this company's own norm. Cheapness signals here deserve extra scrutiny.
Yield Dislocation -1.49σ Dividend yield vs own 10-yr norm
Drawdown Score +0.03σ Distance from line vs own history
Sector-Relative +0.52σ Vs sector median this week
Buyback Acceleration -0.0pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History -1.3pp Vs own recent annual mean
Earnings Quality Deteriorating Accrual gap trend (+3.5pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Historical Touches

AZN has crossed below its 200-week MA 20 times with an average 1-year return of +21.3% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Apr 1994May 199433.0%+50.6%+5114.1%
May 1994Jun 199422.6%+49.3%+5009.4%
Feb 2000Mar 200036.2%+31.5%+1264.4%
Jun 2002May 20035130.7%+9.4%+933.7%
Jun 2003Jun 200310.7%+14.3%+935.2%
Jul 2003Sep 200376.1%+10.8%+970.9%
Sep 2004Nov 200479.0%+17.4%+886.9%
Nov 2004Feb 20051516.0%+17.4%+947.4%
Mar 2005Apr 200523.3%+33.4%+918.2%
Nov 2007Nov 200734.0%-0.7%+745.5%
Dec 2007Jun 20082919.9%-10.0%+737.3%
Jul 2008Jul 200810.1%+4.5%+711.6%
Sep 2008Jun 20093930.5%+5.2%+703.4%
Jun 2009Jul 200922.5%+14.4%+709.0%
Sep 2009Oct 200910.6%+22.9%+691.1%
May 2010May 201043.0%+29.1%+706.7%
May 2012Jun 201211.4%+35.7%+642.1%
Jun 2016Jun 201632.0%+27.9%+339.0%
Oct 2016Feb 20171511.1%+22.8%+323.6%
Aug 2017Aug 201731.3%+40.9%+297.2%
Average10—+21.3%—

Frequently Asked Questions

Is AZN below its 200-week moving average?

No. AstraZeneca PLC (AZN) is currently 23.2% above its 200-week moving average of $149.70. It would need to fall to $149.70 to cross below the line.

What is AZN's 200-week moving average price?

AstraZeneca PLC's 200-week moving average is $149.70 as of 2026-11-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when AZN drops below its 200-week moving average?

AZN has crossed below its 200-week moving average 20 times in our data. On average, buying at that moment produced a one-year return of +21.3%. These dips have historically been decent entry points. These episodes lasted 10 weeks on average.

Is AZN a good value right now?

Here's what our data says about AZN as of 2026-11-13: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 67. Free cash flow yield is 2.0%. Return on equity is 22.6%. Price-to-book is 5.5x. This is not a buy or sell recommendation — always do your own research.

How does AZN compare to the S&P 500?

Over the past 32.7 years, $100 invested in AZN would have grown to $5109, compared to $2964 for the S&P 500. That's 12.8% annualized vs 10.9% for the index. AZN has outperformed the broader market over this period.

Does AZN pay a dividend?

Yes. AstraZeneca PLC currently pays a dividend yield of 174.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-11-13